tbuckley/cabot-search huggingface dataset:
mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland
Authors: Matthias Peter Hilty, Stefanie Keiser, Pedro D. Wendel Garcia, André Moser, Reto A. Schuepbach, Matthias P. Hilty, Reto A. Schüpbach, Pedro D. Wendel Garcia, Thierry Fumeaux, Philippe Guerci, Jonathan Montomoli, Reto A. Schüpbach, Silvio Brugger, Jan Bartussek, Sascha David, Stefanie Keiser, Anne-Aylin Sigg, Annelies Zinkernagel, Mallory Moret-Bochatay, Bernd Yuen, Thomas Hillermann, Anette Ristic, Michael Sepulcri, Miodrag Filipovic, Urs Pietsch, Petra Salomon, Iris Drvaric, Peter Schott, Severin Urech, Adriana Lambert, Lukas Merki, Marcus Laube, Frank Hillgaertner, Marianne Sieber, Alexander Dullenkopf, Lina Petersen, Serge Grazioli, Peter C. Rimensberger, Isabelle Fleisch, Jerome Lavanchy, Marie-Helene Perez, Katharina Marquardt, Karim Shaikh, Hermann Redecker, Michael Stephan, Jan Brem, Bjarte Rogdo, Andre Birkenmaier, Friederike Meyer zu Bentrup, Patricia Fodor, Pascal Locher, Martin Siegemund, Nuria Zellweger, Stephan M. Jakob, Yok-Ai Que, Marie-Madlen Jeitziner, Beatrice Jenni-Moser, Jan Wiegand, Christian Bürkle, Gian-Reto Kleger, Marilene Franchitti Laurent, Jean-Christophe Laurent, Tomislav Gaspert, Marija Jovic, Michael Studhalter, Christoph Haberthuer, Roger F. Lussman, Daniela Selz, Didier Naon, Andrea Glotta, Samuele Ceruti, Julien Marrel, Mirko Brenni, Rolf Ensner, Marc Michot, Nadine Gehring, Antje Heise, Tobias Huebner, Thomas A. Neff, Sara Cereghetti, Filippo Boroli, Jerome Pugin
Journal: Intensive Care Medicine (2022)
An open-label, single-center, phase II study of exploration on optimizing the administration time of fruquintinib combined with camrelizumab in the third-line treatment of MSS advanced colorectal cancer.
Authors: Yifu He
Journal: Journal of Clinical Oncology (2022)

TPS225 Background: Immune checkpoint inhibitors monotherapy has limited clinical benefits in patients with MSS or pMMR metastatic colorectal cancer (CRC), which may be attributed to low level of tumor-infiltrating lymphocytes in MSS advanced CRC. Combination immunotherapy is changing the landscape of cancer treatment, especially combination of immunotherapy with small molecule angiogenesis inhibitors. Preclinical studies have shown that there is a time window from anti-angiogenesis to vascular normalization and this has been initially demonstrated in the clinical study of breast cancer. However, the time window is rarely considered in clinical practice. It is necessary to explore the optimal administration timing of angiogenesis inhibitors when combined with immunotherapy. Here, we conduct an open-label, single-center, phase II study to explore the issue. Methods: Patients eligible for the trial are included: 1) pathologically confirmed advanced colon or rectal adenocarcinoma, MSS or pMMR; 2) previously received only 2 standard regimens after recurrence or metastasis; 3) aged 18-70 years (boundary value included); 4) ECOG performance status of 0 or 1; 5) at least 3 months of survival expectations; 6) patient must present with measurable lesions according to the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST version 1.1; 7) patients with asymptomatic central nervous system metastases or asymptomatic brain metastases after treatment, with stable disease for at least 3 months, and need not be treated with steroids for at least 4 weeks; 8) had adequate organ function before the enrollment; 9) patients of reproductive age should agree to use effective contraceptive measures from the time of signing the informed form until 3 months after the last dose; 10) sign an informed consent form voluntarily, and be willing to and be able to follow and complete all experimental procedures. The patients enrolled were given oral fruquintinib (3 mg, qd, for 2 consecutive weeks, and then discontinued for 1 week, in 3 weeks [21 days] cycle); on the day 5, administered with intravenous camrelizumab (200mg, once every 3 weeks). The treatment was administered continuously until disease progression, unacceptable toxicity, or required withdrawal from patients. The primary endpoint is progression free survival (PFS), and the secondary endpoints are overall survival (OS), objective response rate (ORR), disease control rate (DCR) and drug safety. As of September 23, 2021, a total of 21 patients have been enrolled. Clinical trial information: ChiCTR2100048528.
Chemotherapy Triggers T Cells to Remodel the Extracellular Matrix and Promote Metastasis
Authors: Mikhail G. Kolonin, Wendy A. Woodward
Journal: Cancer Research (2022)

Abstract Chemotherapy can impede cancer progression and is a well-demonstrated component of curative care for some patients with nonmetastatic cancer. However, cancer often relapses in high-risk patients due to acquired chemoresistance and progression to an incurable metastatic stage. There is building evidence from mouse models suggesting a possible stimulatory effect of chemotherapy on metastasis. While clinical trial data from patients with cancer supports the benefits of chemotherapy, the potential adverse effects of chemotherapeutics in a yet unidentified subset of patients are important to consider. In a study by Haj-Shomaly and colleagues, the interaction between the immune system and extracellular matrix remodeling is investigated for its role in the process. The study sheds light on the role of lysyl oxidase secreted by CD8+ T cells in priming the lung microenvironment for metastatic cell seeding, which may represent a targetable axis to further enhance the efficacy of chemotherapy agents. See related article by Haj-Shomaly et al., p. 278
CD40 ligand enhances prostaglandin E2 and thromboxane A2 by stimulating cyclooxygenase-2 in endothelial cells Christoph D. Garlichs, Alexander Schmeisser, Tobias Geis, Saeed Eskafi, Heike Kloos, Margarete Goppelt-Struebe, Josef Ludwig, Werner G. Daniel. University Erlangen-Nuremberg, Clinic of Internal Medicine II, Erlangen, Germany
Journal: Journal of the American College of Cardiology (2001)
Quantification of regurgitant orifice area and flow rate using the centerline velocity gradient from color M-mode doppler: Computational fluid dynamics simulations and in vitro validation study Dimitri Deserranno, Neil L. Greenberg, Mario J. Garcia, George P. Chatzimavroudis, James D. Thomas. Cleveland Clinic Foundation, Cleveland, OH, Cleveland State University, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Abstract 17148: Association of Atrial Fibrillation With Short-Term Outcomes in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction
Authors: Srikanth Yandrapalli, Amole Ojo, Prakash Harikrishnan, Venkat L Vuddanda, Mohammed Karim, Wilbert S Aronow, William Frishman, Ali Ahmed, Gregg C Fonarow, Gregg M Lanier, Sei Iwai, Jason T Jacobson
Journal: Circulation (2018)

Background: Atrial fibrillation (AF) is frequently present in patients with heart failure (HF) with preserved ejection fraction (HFpEF). The association of AF with short term outcomes in patients hospitalized for HFpEF is not well studied. Methods: We queried the United States Nationwide Readmissions Database year 2014 using appropriate ICD-9 codes to identify a weighted sample of adult patients hospitalized for HFpEF. Patients with concomitant diagnoses of HF with reduced ejection fraction (HFrEF) were excluded. The primary outcome was a composite of in-hospital death or a 30-day readmission for HF. Secondary outcomes studied were individual outcomes along with composites of in-hospital death or a 30-day readmission for any cause or cardiac etiologies. Survey specific adjusted multivariable logistic regression models were used to analyze the association of AF with outcomes. Results: Of 229,098 patients (mean age 76 years, 38% men) who were hospitalized for HFpEF during the study period, AF was present in 45.3% (N=103,852). Patients with AF were older (mean age 80 vs 72 years, p&lt;.001) and more likely men (39% vs 37.5%, p&lt;.001) compared to patients without AF. Primary outcome occurred in 9.5% patients with AF and in 8.0% patients without AF (p&lt;0.001). After adjusting for patient demographics, comorbidities, complications, and hospital characteristics, AF was associated with 17% higher odds of the primary outcome (OR 1.17, 95% CI 1.11-1.23), 20% higher odds of in-hospital death (OR 1.20, 95% CI 1.07-1.34), and 17% higher odds of a 30-day readmission for HF (OR 1.17, 95% CI 1.10-1.25). Similar results were noted for other outcomes; TABLE . Conclusion: AF was associated with significantly worse short-term outcomes in patients hospitalized for HFpEF. Additional strategies are needed to improve outcomes in HFpEF patients with AF. Future prospective studies need to examine if AF ablation in HFpEF may improve outcomes as in HFrEF.
The beneficial effect of spironolactone on heart rate variability in severe congestive heart failure Ali R. Bilge, Badreddine Ahmadoun, Pierre Block, Daniel Duprez, Agnessa Babloyantz, Luc A. Pierard. University hospital cardiology department, Liege, Belgium, Brussels University Solvay Institute, Brussels, Belgium
Journal: Journal of the American College of Cardiology (2001)
Instructions for Authors
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 250: Canonical Transient Receptor Potential Channel 6 Ameliorates Increased Cardiac S-nitrosylation in Duchenne Muscular Dystrophy
Authors: Grace E Kim, Heaseung S Chung, Ronald J Holewinski, Guangshuo Zhu, Vidya Venkatraman, Djahida Bedja, Jennifer E Van Eyk, David A Kass
Journal: Circulation Research (2017)

Duchenne muscular dystrophy (DMD) is an X-linked disorder that markedly weakens skeletal and cardiac muscle to cause early death. Its elimination of dystrophin disrupts nitric oxide (NO) signaling and amplifies intracellular Ca 2+ responses to mechanical load. We have shown the latter is linked to hyperstimulated transient receptor potential canonical 6 (TRPC6) cation channels. As Ca 2+ also activates NO synthase, we hypothesized TRPC6 couples to redox-dependent nitrosative stress to broadly impact protein S-nitrosylation (SNO). Using an unbiased, dual-labeling proteomic strategy we identified 1276 SNO sites on 491 proteins in DMD hearts (dystrophin/utrophin +/- ), of which 102 sites among 69 proteins were unique to DMD. Many of the targeted proteins were mitochondrial or metabolic regulators and sarcomere proteins - including titin, myosin binding protein-C, α-myosin heavy-chain, and tropomyosin α1 - that were hyper-nitrosylated. A key redox regulator peroxiredoxin1 was also hyper-nitrosylated at Cys173, a site previously shown to be a requisite regulator of its dimerization and enzymatic activity. DMD mice were then crossed into a Trpc6 -/- background, and proteomic analysis now found 70% of SNO targeted residues in DMD were reversed towards normal (p&lt;0.01, χ 2 ). Trpc6 deletion improved left ventricular dilation (13.7±1.2mm, 22.4±3.9mm, 15.3±2.3mm; p&lt;0.01), fractional shortening (58.5±0.5%, 50.3±1.0%, 59.6±1.2%, p&lt;0.001), and fibrosis (2.3±0.9%, 6.2±0.9%, 3.7±0.6%; p&lt;0.0001) in WT, DMD and DMD-TRPC6 -/- respectively (1-way ANOVA), and reversed pro-fibrotic gene activation (connective tissue growth factor, fibronectin1 and osteopontin). These results provide the first broad-based SNO analysis of the DMD heart, and support linkage between abnormal calcium via TRPC6, nitrosative stress and cardiac disease.
A glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence based on the current epidemiological data.
Authors: Sri Harsha Tella, Kristin Mara, Anuhya Kommalapati, Sakti Chakrabarti, Aakash Desai, Patrick Walsh McGarrah, Zhaohui Jin, Amit Mahipal
Journal: Journal of Clinical Oncology (2022)

248 Background: Esophageal carcinoma is the 6th most common cause of death worldwide. While squamous cell carcinoma (SCC) was the most common among the histologic subtypes in the 20th century, recent reports have demonstrated an increased incidence of adenocarcinoma in both Eastern and Western world. With this changing paradigm of esophageal carcinoma, it is important to estimate the future burden of esophageal carcinoma by histology, age, sex, and race, that could help plan prevention, control, and treatment strategies for this cancer. Methods: We used Surveillance, Epidemiology, and End Results (SEER) 14 registries to obtain incidence data from 2000 to 2016. We applied age-period-cohort models to estimate future esophageal carcinoma incidence rates and the estimated disease burden by multiplying incidence forecasts by corresponding US Census population projections. Results: Our estimate suggests that the incidence (per 100,000 persons) of esophageal adenocarcinoma is increasing in people within the age group of 40-65 years. Our prediction showed that the incidence will increase from 2.12 in 2021 to 2.82 in 2030 (3.2% per year, 95% CI –2.3% to 9.1%, p=0.26). Notably, we noticed a similar marginal increase in incidence among Asians, Black, and Whites in the 40-65 years age group (3.1%, 3.2%, and 4.2%, per year, respectively). White males aged &gt;65 years had the highest incidence of esophageal adenocarcinoma (17.34 in 2021), and incidence decreased 1.3% per year. We noticed a marginally decreased incidence in Black male (-1.1% per year, p=0.71) and Asian male (-3.9% per year, p=0.17) population aged &gt;65 years. Interestingly, we found a decrease in the incidence of SCC in the current age groups 40-65 (-2.7% per year, p=0.31) and &gt;65 years (-4.6% per year, p=0.081). We observed that Asians had the greatest decrease in incidence (-4.3% per year) as compared to that of Blacks (-4.2% per year) and Whites (-2.9% per year), although there was no statistically significant difference in the annual decrease among races. Conclusions: In our study of esophageal cancer, we predict an increased incidence of adenocarcinoma histology subtype in the younger age group (40-65 years) while the SCC subtype will have a decreased trend. Strategies to prevention esophageal adenocarcinoma, including dietary changes, should preferentially target patients &lt;65 years of age.[Table: see text]
Trained and supervised physician assistants can safely perform diagnostic cardiac catheterization and coronary angiography Richard A. Krasuski, John J. Warner, Andrew Wang, J. Kevin Harrison, John F. Bolles, Erica L. Moloney, Carole Ross, Thomas M. Bashore, Michael H. Sketch, Jr.. Duke University Medical Center, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Some Conclusions on Cancer.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SARS-CoV-2 B cell receptor signatures in at-risk populations
Authors: Andrew I. Flyak
Journal: Journal of Clinical Investigation (2020)

Many individuals possess B cells capable of recognizing epitopes on the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this issue of the JCI, Paschold and Simnica et al. interrogated the frequency of SARS-CoV-2-specific B cell receptor rearrangements in healthy subjects based on age and cancer status. The authors found that while SARS-CoV-2-specific antibody signatures can be identified in the repertoires of young, healthy individuals, such sequences are less frequent in elderly subjects or patients with cancer. Overall, this study sheds light on B cell repertoire restrictions that might lead to an unfavorable clinical course of coronavirus disease 2019 infection in at-risk populations.
Superior safety of optically-guided versus traditional transesophageal echocardiography Marco R. Di Tullio, Jonathan E. Aviv, Ian S. Storper, Christine D. Bussey, Deborah R. Gersony, Sang Kim, Joel Guss, Mark Murphy, Steven Corwin, Shunichi Homma. Columbia University, New York, NY
Journal: Journal of the American College of Cardiology (2001)
No Added Value of Duloxetine in Patients With Chronic Pain due to Hip or Knee Osteoarthritis: A <scp>Cluster‐Randomized</scp> Trial
Authors: Jacoline J. van den Driest, Dieuwke Schiphof, Aafke R. Koffeman, Marc A. Koopmanschap, Patrick J. E. Bindels, Sita M. A. Bierma‐Zeinstra
Journal: Arthritis & Rheumatology (2022)

To assess the effectiveness of duloxetine in addition to usual care in patients with chronic osteoarthritis (OA) pain. The cost-effectiveness and whether the presence of symptoms of centralized pain alters the response to duloxetine were secondary objectives.We conducted an open-label, cluster-randomized trial. Patients with chronic hip or knee OA pain who had an insufficient response to acetaminophen and nonsteroidal antiinflammatory drugs were included. Randomization took place at the general practice level, and patients received duloxetine (60 mg/day) in addition to usual care or usual care alone. The presence of centralized pain was defined as a modified PainDETECT Questionnaire score >12. The primary outcome measure was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores (scale 0-20) at 3 months after the initiation of treatment. Our aim was to detect a difference between the groups of a clinically relevant effect of 1.9 points (effect size 0.4). We used a linear mixed model with repeated measurements to analyze the data.In total, 133 patients were included, and 132 patients were randomized into treatment groups. A total of 66 patients (at 31 practices) were randomized to receive duloxetine in addition to usual care, and 66 patients (at 35 practices) were randomized to receive usual care alone. We found no differences in WOMAC pain scores between the groups at 3 months (adjusted difference -0.58 [95% confidence interval (95% CI) -1.80, 0.63]) or at 12 months (adjusted difference -0.26 [95% CI -1.86, 1.34]). In the subgroup of patients with centralized pain symptoms, we also found no effect of duloxetine compared to usual care alone (adjusted difference -0.32 [95% CI -2.32, 1.67]).We found no effect of duloxetine added to usual care compared to usual care alone in patients with chronic knee or hip OA pain. Another trial including patients with centralized pain symptoms should be conducted to validate our results.
MAN'S CONQUEST OF ALTITUDE
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Medical Literature.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal